BfArM — authorised 22 March 2017
- Marketing authorisation holder: PFIZER EUROPE MA EEIG
- Status: approved
BfArM authorised Xeljanz on 22 March 2017
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. BfArM authorised it on 22 March 2017.
PFIZER EUROPE MA EEIG holds the German marketing authorisation.